Drug Trial Radar · NCT06577441
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
54
Planned (sponsor's estimate)
Start
Jun 12, 2025
Primary completion
Mar 1, 2027
Study completion Mar 1, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Aug 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II MyeloMATCH treatment trial compares the usual treatment of cedazuridine-decitabine (ASTX727) to the combination treatment of ASTX727 and enasidenib in treating patients with higher-risk, IDH2-mutated myelodysplastic syndrome (MDS). ASTX727 is a combination of two drugs, decitabine and cedazuridine. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Enasidenib is an enzyme inhibitor that may stop the growth of cells by blocking some of the enzymes needed for cell growth. Giving ASTX727 in combination with enasidenib may be effective in treating patients with higher-risk IDH2-mutated MDS.
Conditions
- Myelodysplastic Syndrome
Interventions
Biospecimen CollectionProcedure
Undergo buccal swab and blood sample collection
Bone Marrow AspirationProcedure
Undergo bone marrow aspiration
Bone Marrow BiopsyProcedure
Undergo bone marrow biopsy
Decitabine and CedazuridineDrug
Given PO
EnasidenibDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete response (CR) rateTime frame: Up to 4 cycles of treatment
Locations
152 sites in 2 countries. Site status is shown where the registry gives one.
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California · Active not recruiting
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California · Recruiting
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
Mills Health Center
San Mateo, California · Active not recruiting
UF Health Cancer Institute - Gainesville
Gainesville, Florida · Recruiting
Miami Cancer Institute
Miami, Florida · Recruiting
Memorial Hospital West
Pembroke Pines, Florida · Recruiting
Phoebe Putney Memorial Hospital
Albany, Georgia · Recruiting
Saint Luke's Cancer Institute - Boise
Boise, Idaho · Recruiting
Kootenai Health - Coeur d'Alene
Coeur d'Alene, Idaho · Recruiting
Saint Luke's Cancer Institute - Fruitland
Fruitland, Idaho · Recruiting
Saint Luke's Cancer Institute - Meridian
Meridian, Idaho · Recruiting
Saint Alphonsus Cancer Care Center-Nampa
Nampa, Idaho · Recruiting
Saint Luke's Cancer Institute - Nampa
Nampa, Idaho · Recruiting
Kootenai Clinic Cancer Services - Post Falls
Post Falls, Idaho · Recruiting
Kootenai Clinic Cancer Services - Sandpoint
Sandpoint, Idaho · Recruiting
Illinois CancerCare-Bloomington
Bloomington, Illinois · Recruiting
Illinois CancerCare-Canton
Canton, Illinois · Recruiting
Illinois CancerCare-Carthage
Carthage, Illinois · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
Swedish Covenant Hospital
Chicago, Illinois · Recruiting
University of Chicago Comprehensive Cancer Center
Chicago, Illinois · Recruiting
Carle at The Riverfront
Danville, Illinois · Recruiting
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois · Recruiting
Decatur Memorial Hospital
Decatur, Illinois · Recruiting
Northwestern Medicine Cancer Center Kishwaukee
DeKalb, Illinois · Recruiting
Illinois CancerCare-Dixon
Dixon, Illinois · Recruiting
Carle Physician Group-Effingham
Effingham, Illinois · Recruiting
Crossroads Cancer Center
Effingham, Illinois · Recruiting
Illinois CancerCare-Eureka
Eureka, Illinois · Recruiting
NorthShore University HealthSystem-Evanston Hospital
Evanston, Illinois · Recruiting
Illinois CancerCare-Galesburg
Galesburg, Illinois · Recruiting
Northwestern Medicine Cancer Center Delnor
Geneva, Illinois · Recruiting
NorthShore University HealthSystem-Glenbrook Hospital
Glenview, Illinois · Recruiting
Northwestern Medicine Glenview Outpatient Center
Glenview, Illinois · Recruiting
Northwestern Medicine Grayslake Outpatient Center
Grayslake, Illinois · Recruiting
NorthShore University HealthSystem-Highland Park Hospital
Highland Park, Illinois · Recruiting
Edward Hines Jr VA Hospital
Hines, Illinois · Recruiting
Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois · Recruiting
Northwestern Medicine Lake Forest Hospital
Lake Forest, Illinois · Recruiting
Showing 40 of 152 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.